Literature DB >> 29181884

miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression.

Foteini D Tsikrika1, Margaritis Avgeris1, Panagiotis K Levis2, Theodoros Tokas2, Konstantinos Stravodimos2, Andreas Scorilas1.   

Abstract

Clinical heterogeneity of bladder cancer prognosis requires the identification of bladder tumors' molecular profile to improve the prediction value of the established and clinically used markers. In this study, we have analyzed miR-221/222 cluster expression in bladder tumors and its clinical significance for patients' prognosis and disease outcome. The study included 387 tissue specimens. Following extraction, total RNA was polyadenylated at 3'-end and reversed transcribed. SYBR-Green based qPCR assays were performed for the quantification of miR-221/222 expression. Extensive statistical analysis was completed for the evaluation of miR-221/222 cluster's clinical significance. The expression of miR-221/222 is significantly downregulated in tumors compared to normal urothelium, while ROC curve and logistic regression analysis highlighted cluster's discriminatory ability. However, miR-222 levels were increased in muscle-invasive (T2-T4) compared to superficial tumors (TaT1), and in high compared to low-grade tumors. Kaplan-Meier survival curves and Cox regression analysis revealed the stronger risk of TaT1 patients overexpressing miR-222 for disease short-term relapse and progression following treatment. Moreover, multivariate Cox models highlighted the independent prognostic value of miR-222 overexpression for TaT1 patients' poor prognosis. Finally, the analysis of miR-222 expression improved significantly the positive prediction strength of the clinically used prognostic markers of tumor stage, grade, EORTC risk-stratification and recurrence at the first follow-up cystoscopy for TaT1 patients' outcome, and resulted to higher clinical net benefit following decision curve analysis. In conclusion, the expression of miR-221/222 cluster is deregulated in bladder tumors and miR-222 overexpression results to a superior positive prediction of TaT1 patients' short-term relapse and progression.
© 2017 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29181884     DOI: 10.1002/gcc.22516

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  11 in total

Review 1.  Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer.

Authors:  Marios A Diamantopoulos; Panagiotis Tsiakanikas; Andreas Scorilas
Journal:  Ann Transl Med       Date:  2018-06

2.  ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression.

Authors:  Maria-Alexandra Papadimitriou; Margaritis Avgeris; Panagiotis K Levis; Theodoros Tokas; Konstantinos Stravodimos; Andreas Scorilas
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-08       Impact factor: 4.553

3.  Quantitative analysis and study of the mRNA expression levels of apoptotic genes BCL2, BAX and BCL2L12 in the articular cartilage of an animal model of osteoarthritis.

Authors:  Aristotelis Kourtis; Panagiotis G Adamopoulos; Apostolos Papalois; Dimitrios C Iliopoulos; George C Babis; Andreas Scorilas
Journal:  Ann Transl Med       Date:  2018-06

Review 4.  microRNA-based diagnostic and therapeutic applications in cancer medicine.

Authors:  Lorenzo F Sempere; Asfar S Azmi; Anna Moore
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-05-17       Impact factor: 9.957

5.  Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy.

Authors:  Shan Zhang; Yaohui Wang; Yan Wang; Jing Peng; Chenwei Yuan; Liheng Zhou; Shuguang Xu; Yanping Lin; Yueyao Du; Fan Yang; Jie Zhang; Huijuan Dai; Wenjin Yin; Jinsong Lu
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

6.  miR-221-3p and miR-222-3p regulate the SOCS3/STAT3 signaling pathway to downregulate the expression of NIS and reduce radiosensitivity in thyroid cancer.

Authors:  Ting Ye; Lili Zhong; Xuemei Ye; Jie Liu; Linfa Li; Heqing Yi
Journal:  Exp Ther Med       Date:  2021-04-19       Impact factor: 2.447

Review 7.  Crucial Roles of microRNA-Mediated Autophagy in Urologic Malignancies.

Authors:  Maolei Shen; Xin Li; Biao Qian; Qiang Wang; Shanan Lin; Wenhao Wu; Shuai Zhu; Rui Zhu; Shankun Zhao
Journal:  Int J Biol Sci       Date:  2021-07-31       Impact factor: 6.580

Review 8.  miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review.

Authors:  Maria Teresa Di Martino; Mariamena Arbitrio; Daniele Caracciolo; Alessia Cordua; Onofrio Cuomo; Katia Grillone; Caterina Riillo; Giulio Caridà; Francesca Scionti; Caterina Labanca; Caterina Romeo; Maria Anna Siciliano; Maria D'Apolito; Cristina Napoli; Martina Montesano; Valentina Farenza; Valentina Uppolo; Michele Tafuni; Federica Falcone; Giuseppe D'Aquino; Natale Daniele Calandruccio; Francesco Luciano; Licia Pensabene; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Mol Ther Nucleic Acids       Date:  2022-02-11       Impact factor: 8.886

9.  The Effect of MCM3AP-AS1/miR-211/KLF5/AGGF1 Axis Regulating Glioblastoma Angiogenesis.

Authors:  Chunqing Yang; Jian Zheng; Yixue Xue; Hai Yu; Xiaobai Liu; Jun Ma; Libo Liu; Ping Wang; Zhen Li; Heng Cai; Yunhui Liu
Journal:  Front Mol Neurosci       Date:  2018-01-09       Impact factor: 5.639

10.  Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis.

Authors:  Yuying Han; Xu Liu; Haihong Ye; Ye Tian; Zhengguo Ji
Journal:  World J Surg Oncol       Date:  2020-11-26       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.